Feb 6, 2023
KYORIN Pharmaceutical, a core compamy in the Kyorin Group, has set a goal of establishing a greater presence in the franchise customer (FC) field (respiratory medicine, urology and otolaryngology), and is working to reinforce its R&D pipeline.
PhⅢ ～ Application submitted
| Stage | Compound / Code |
Origin | Features |
|---|---|---|---|
| PhⅢ (9/2022) |
KRP-R120 / Interstitial lung disease: ILD (pulmonary sarcoidosis) |
aTyr pharma | It is a fusion protein drug having the action to suppress, by binding to neuropilin-2 (NRP2) receptor, the excessive activation of immune cells, and is a potential first-in-class therapy to treat inflammatory diseases such as pulmonary sarcoidosis. |
POC Project (PhⅠ ～ PhⅡ)
| Stage | Compound / Code |
Origin | Features |
|---|---|---|---|
| PhⅠ (8/2022) |
KRP-114VP / Overactive bladder |
Merck | Additional Indication for Beova in pediatric patients. |
| PhⅠ (4/2021) |
KRP-A218 | In-house | It is antiviral drug that suppresses viral growth by targeting host molecules. |
Licensing development (License-in)
| Stage/Overseas | Compound・ Code/Therapy area |
Origin | Features |
|---|---|---|---|
| PhⅡ (12/2019) ASKA Pharmaceutical |
AKP-009 / Benign Prostatic Hyperplasia |
ASKA Pharmaceutical | Novel androgen receptor modulator mode of action with the potential to exhibit prostatic shrinkage and to improve urinary function as a novel therapeutic agent for Benign Prostatic Hyperplasia. |
* Additional Ph I study at a higher dose has been completed (ASKA)
Licensing development (License-out)
| Stage/Overseas | Compound・ Code/Therapy area |
Licensee | Origin | Features |
|---|---|---|---|---|
| PhⅠ | KRP-203 | Priothera | In-house | Sphingosine-1-Phosphate Receptor Agonist |
